Abstract: Compositions of proteoglycans and core proteins thereof and related methods of treating subjects, e.g., patients, are described. The method may include applying a composition to an eye of a subject before, during, and/or after an intraocular medical procedure. The composition may comprise a proteoglycan or core protein thereof, such as decorin proteoglycan or decorin core protein, and a pharmaceutically-acceptable salt. The composition may be in the form of an aqueous solution, viscoelastic gel, or viscoelastic film, for example. Further methods are described that include treating donor corneal tissue with a composition comprising a proteoglycan or core protein thereof. The treated donor corneal tissue may be used as or in a corneal graft, such as during endothelial keratoplasty.

Abstract: Compositions of proteoglycans and core proteins thereof and related methods of treating subjects, e.g., patients, are described. The method may include applying a composition to an eye of a subject before, during, and/or after an intraocular medical procedure. The composition may comprise a proteoglycan or core protein thereof, such as decorin proteoglycan or decorin core protein, and a pharmaceutically-acceptable salt. The composition may be in the form of an aqueous solution, viscoelastic gel, or viscoelastic film, for example. Further methods are described that include treating donor corneal tissue with a composition comprising a proteoglycan or core protein thereof. The treated donor corneal tissue may be used as or in a corneal graft, such as during endothelial keratoplasty.

Abstract: Disclosed herein are collagen films which rapidly dissolve at 35° C. Also disclosed are methods for the preparation of the collagen films and their use as a vehicle for delivering a dose of therapeutic compound to a specific tissue site.

Abstract: Disclosed herein are collagen films which rapidly dissolve at 35° C. Also disclosed are methods for the preparation of the collagen films and their use as a vehicle for delivering a dose of therapeutic compound to a specific tissue site.

Abstract: A method of smoothing irregular corneal surfaces and removing protuberances from corneal surfaces by photoablative eximer laser keratectomy is provided. Collagen compositions for use in making collagen modulators useful in photoablative procedures are described. These compositions are applied to irregular corneal surfaces in sufficient amounts to at least fill in depressions or other irregularities on a corneal surface and are converted into a modulator, as a gel or polymerized film, prior to photoablation. The collagen modulators facilitate the photoablative smoothing of irregular corneal surfaces and protect adjacent corneal tissue from undesired photoablation.

Abstract: Disclosed herein are collagen films which rapidly dissolve at 35° C. Also disclosed are methods for the preparation of the collagen films and their use as a vehicle for delivering a dose of therapeutic compound to a specific tissue site.

Abstract: A method of smoothing irregular corneal surfaces and removing protuberances from corneal surfaces by photoablative eximer laser keratectomy is provided. Collagen compositions for use in making collagen modulators useful in photoablative procedures are described. These compositions are applied to irregular corneal surfaces in sufficient amounts to at least fill in depressions or other irregularities on a corneal surface and are converted into a modulator, as a gel or polymerized film, prior to photoablation. The collagen modulators facilitate the photoablative smoothing of irregular corneal surfaces and protect adjacent corneal tissue from undesired photoablation.

Abstract: A method of smoothing irregular corneal surfaces and removing protuberances from corneal surfaces by photoablative excimer laser keratectomy is provided. Collagen compositions for use in making collagen modulators useful in photoablative procedures are described. These compositions are applied to irregular corneal surfaces in sufficient amounts to at least fill in depressions or other irregularities on a corneal surface and are converted into a modulator, as a gel or polymerized film, prior to photoablation. The collagen modulators facilitate the photoablative smoothing of irregular corneal surfaces and protect adjacent corneal tissue from undesired photoablation.

Abstract: A method for treating corneal stromal wounds to promote regeneration of the affected tissue is provided. This method employs recombinant human epidermal growth factor.